



Vibrant Wellness is pleased to present to you, 'Mycotoxins', to help you make healthy lifestyle, dietary and treatment choices in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being.

The Vibrant Mycotoxins is a test to identify and quantify the level of a large set of mycotoxins from both food and environmental molds. The panel is designed to give a complete picture of an individual's levels of these mycotoxins in urine. The results are provided in 3 tables subgrouping the mycotoxins into Aflatoxins, Trichothecenes and Other Mycotoxins

Interpretation of Report: The report begins with the Mycotoxins summary page which lists only the mycotoxins whose levels are high or moderate in the reference range. Following this section is the complete list of the mycotoxins along with the corresponding species and their levels normalized to urinary creatinine, in a tabular form to enable a full overview along with the reference ranges. The level of the mycotoxin has a green, yellow or red highlight around the cell indicating – Mild (Low mold diet intake), Moderate or High exposure to the particular mycotoxin. Additionally, the previous value is also indicated to help check for improvements every time the test is ordered.

The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile. Testing for the Mycotoxins panel is performed by Vibrant America, a CLIA certified lab CLIA#:05D2078809. Vibrant Wellness provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website at www.vibrant-wellness.com. By accessing, browsing, or otherwise using the report or website or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to accept these terms, you shall not access, browse, or use the report or website. The statements in this report have not been evaluated by the Food and Drug Administration and are only meant to be lifestyle choices for potential risk mitigation. Please consult your physician/dietitian for medication, treatment, or lifestyle management. This product is not intended to diagnose, treat, or cure any disease.

Please Note - It is important that you discuss any modifications to your diet, exercise and nutritional supplementation with your physician before making any changes.

VibrantWellness 1360 Bayport Ave, Ste B. San Carlos, CA 94070 1(866) 364-0963 | support@vibrant-wellness.com | www. vibrant-wellness.com

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST	MALE	1998-03-15	2008260002	08-25-2020 14:55

Mycotoxins Summary

Test Name	Species Name	In Control	Moderate	High	Current Level	Previous Level (08/26/202 0)
Sterigmatocystin (ng/g)	Aspergillus, Penicillium, Bipolaris	≤0.40	0.41~0.80	≥0.81	7.77	6.55
Zearalenone (ng/g)	Fusarium	≤0.50	0.51~1.00	≥1.01	3.41	3.19
Enniatin B1 (ng/g)	Fusarium	≤0.10	0.11~0.40	≥0.41	3.70	3.08
Roridin E (ng/g)	Fusarium, Myrothecium, Stachybotrys	≤1.00	1.01~2.00	≥2.01	5.72	6.11
Verrucarin A (ng/g)	Fusarium, Myrothecium, Stachybotrys	≤1.00	1.01~2.00	≥2.01	7.97	5.03
Nivalenol (NIV) (ng/g)	Fusarium	≤2.40	2.41~4.80	≥4.81	5.81	3.80
diacetoxyscirpenol (DAS) (ng/g)	Fusarium	≤3.20	3.21~6.40	≥6.41	7.85	4.80
T-2 toxin (ng/g)	Fusarium	≤0.10	0.11~0.30	≥0.31	4.18	3.83
Satratoxin G (ng/g)	Stachybotrys chartarum	≤0.10	0.11~0.30	≥0.31	5.96	5.90
Satratoxin H (ng/g)	Stachybotrys chartarum	≤0.10	0.11~0.30	≥0.31	5.80	4.14
Isosatratoxin F (ng/g)	Stachybotrys chartarum	≤0.10	0.11~0.30	≥0.31	3.73	7.72
Urine Creatinine (mg/ml)		0.25~2.16		≤0.24 ≥2.17	5.20	5.85

VibrantWellness 1360 Bayport Ave, Ste B. San Carlos, CA 94070 1(866) 364-0963 | support@vibrant-wellness.com | www. vibrant-wellness.com

	FIRST NAME GEND TEST MALE		E OF BIRTH 1-03-15	ACCESSI 2008260		ATE OF SERVICE
Mycotoxins - Moderate						
Test Name	Species Name	In Control	Moderate	High	Current Level	Previous Level (08/26/202 0)
Aflatoxin M1 (ng/g)	Aspergillus	≤4.80	4.81~9.60	≥9.61	5.64	4.49
Aflatoxin G1 (ng/g)	Aspergillus	≤4.90	4.91~9.80	≥9.81	6.10	5.89
Ochratoxin A (ng/g)	Aspergillus, Penicillium	≤5.10	5.11~10.20	≥10.21	6.97	7.59
Fumonisins B2 (ng/g)	Fusarium	≤5.40	5.41~10.80	≥10.81	6.55	3.42
Roridin H (ng/g)	Stachybotrys chartarum	≤6.30	6.31~12.60	≥12.61	7.11	5.62
Roridin L-2 (ng/g)	Stachybotrys chartarum	≤5.10	5.11~10.20	≥10.21	5.58	7.53



LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST	MALE	1998-03-15	2008260002	08-25-2020 14:55

Mycotoxins Complete List

Aflatoxin							
Test Name (ng/g)	Species Name	In Control	Moderate	High	Current Level	Previous Level (08/26/202 0)	
Aflatoxin M1	Aspergillus	≤4.80	4.81~9.60	≥9.61	5.64	4.49	
Aflatoxin B1	Aspergillus	≤5.20	5.21~10.40	≥10.41	5.16	3.02	
Aflatoxin B2	Aspergillus	≤6.10	6.11~12.20	≥12.21	5.94	5.70	
Aflatoxin G1	Aspergillus	≤4.90	4.91~9.80	≥9.81	6.10	5.89	
Aflatoxin G2	Aspergillus	≤8.10	8.11~16.20	≥16.21	5.89	7.88	

Comments

Aflatoxin M1

Aflatoxins are secondary metabolites produced by different strains Aspergillus species, widely found as contaminants in a great variety of crops—cereals, oilseeds, tree nuts and spices. Among these toxins, Aflatoxin M1 (AFM1) is the principal hydroxylated aflatoxin metabolite of Aflatoxin B1 (AFB1), the most recurrent and most harmful aflatoxin present in the milk of dairy cows fed a diet contaminated with AFB1. Carry-over of AFB1 as AFM1 in the milk of dairy cows has been established to range from 0.3% to 6.2%. Due to the high stability of AFM1 towards milk processing technologies, such as pasteurization, ultra-high temperature heating (UHT), and other processing methods, this mycotoxin can be found not only in milk, but also in dairy products, usually at higher concentration than that found in raw milk. In addition, AFM1 is found in human breast milk too. This mycotoxin has become a real public health concern, especially for infants and young children. It is considered that infants are more exposed to AFM1 contamination by breast milk intake than that using infant formula.¹ Moreover, international agency for research on cancer (IARC) classified AFB1 and AFM1 as human carcinogens belonging to Group 1 and Group 2B, respectively.²

Aflatoxin G1

Aflatoxins are naturally occurring Mycotoxins that are produced by Aspergillus species of fungi. Aflatoxin G1 (AFG1) is one of the four major naturally known aflatoxins produced by the Aspergillus species. Aflatoxins may be present in a wide range of food commodities, particularly cereals, oil seeds, spices and tree nuts like maize, groundnuts (peanuts), pistachios, chilies, black pepper, dried fruit and figs etc. It has also been detected in milk and milk products. Less is known about the chronic toxicity of aflatoxin G1, but these are also thought to be carcinogens, though probably a little less potent than B1.

Vibrant Wellness

1(866) 364-0963 | support@vibrant-wellness.com | www. vibrant-wellness.com

AST NAME ATIENT	FIRST NAMEGETESTMA		E OF BIRTH B-03-15	ACCESSI 2008260		DATE OF SERVICE
)ther						
Test Name (ng/g)	Species Name	In Control	Moderate	High	Current Levei	Previous Level (08/26/202 0)
Ochratoxin A	Aspergillus, Penicilliu	m ≤5.10	5.11~10.20	≥10.21	6.97	7.59
Sterigmatocystin	Aspergillus, Penicilliu Bipolaris	^{m,} ≤0.40	0.41~0.80	≥0.81	7.77	6.55
Zearalenone	Fusarium	≤0.50	0.51~1.00	≥1.01	3.41	3.19
Enniatin B1	Fusarium	≤0.10	0.11~0.40	≥0.41	3.70	3.08
Fumonisins B1	Fusarium	≤4.60	4.61~9.20	≥9.21	3.65	6.43
Fumonisins B2	Fusarium	≤5.40	5.41~10.80	≥10.81	6.55	3.42
Fumonisins B3	Fusarium	≤8.10	8.11~16.20	≥16.21	3.91	7.91
Citrinin	Penicillium	≤9.40	9.41~18.80	≥18.81	3.06	3.25
Patulin	Penicillium	≤8.70	8.71~17.40	≥17.41	5.47	7.64
Gliotoxin	Aspergillus	≤155.90	155.91~311.80	≥311.81	6.18	6.13
Mycophenolic Acid	Aspergillus, Penicilliu	m ≤4.80	4.81~9.60	≥9.61	3.74	6.37
Dihydrocitrinone	Aspergillus, Penicilliu Monascus	^m , ≤12.40	12.41~24.80	≥24.81	7.93	5.34
Chaetoglobosin A	Chaetomium globosu	m ≤23.90	23.91~47.80	≥47.81	7.82	7.74

Comments

Ochratoxin A

Members of the ochratoxin A have been found as metabolites of many different species of Aspergillus and Penicillium. The level of Ochratoxin A production also influenced by the substrate on which the molds grow as well as the moisture level, temperature, and presence of competitive microflora interact to influence the level of toxin produced. Ochratoxin A has been found in barley, oats, rye, wheat, coffee beans, and other plant products, with barley having a particularly high likelihood of contamination. Ochratoxin has been detected in blood and other animal tissues and in milk, including human milk. Ochratoxin A is a nephrotoxin to all animal species studied to date and is most likely toxic to humans, who have the longest half-life for its elimination of any of the species. It is frequently found in pork intended for human consumption. Ochratoxin is believed to be responsible for a porcine nephropathy that has been studied intensively in the Scandinavian countries. The disease is endemic in Denmark, where rates of porcine nephropathy and ochratoxin contamination in pig feed are highly correlated. In addition to being a nephrotoxin, animal studies indicate that ochratoxin A is a liver toxin, an immune suppressant, a potent teratogen, and a carcinogen.³



LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST	MALE	1998-03-15	2008260002	08-25-2020 14:55

Sterigmatocystin

Sterigmatocystin, a related dihydrofuran toxin, is a late metabolite in the aflatoxin pathway and is also produced as a final biosynthetic product by a number of species such as Aspergillus Penicillium, and Bipolaris. STC is a possible human carcinogen (2B) according to IARC classification and showed immunotoxic and immunomodulatory activity, together with mutagenic effects. It might be found in numerous substrates, from foods and feeds to chronically damp building materials and indoor dust. Due to the structural similarities, aflatoxins and STC share relevant toxic effects, including genotoxicity and carcinogenicity. However, in contrast to aflatoxins, only limited information on occurrence and toxicity of STC is available. Liver and kidneys are the target organs of acute toxicity of STC. However, the acute oral toxicity is relatively low (range between 120 and 166 mg/kg body weight).⁴

Zearalenone

Zearalenone (ZEA) is a non-steroidal estrogenic mycotoxin. It is produced principally by Fusarium molds, and consequently occurs wherever DON occurs, most notably as a contaminant of maize, wheat, barley, oats, rye, sorghum, millet, and rice. ZEA and its metabolites can bind to estrogen receptors, resulting in various changes in the reproductive organs. In addition, however, ZEA is a competitive substrate for enzymes involved in steroid synthesis and metabolism and therefore has the potential to act as an endocrine disruptor.⁵

Enniatin B1

Mycotoxin enniatin B (ENN B) is a secondary metabolism product by Fusarium fungi. It is a well-known antibacterial, antihelmintic, antifungal, herbicidal, and insecticidal compound. It has been found as a contaminant in cereal grains, animal feeds and several food commodities worldwide, co-occurring with other mycotoxins. Moreover, they are commonly found in fish, dried fruits, nuts, spices, cocoa, coffee products, etc. Food processing techniques such as cooking, baking, frying, roasting, etc. do not affect their chemical structure; so, detoxification strategies to mitigate the risks of ENNs presence in foods and feed may be difficult. Several in vitro and in vivo studies have revealed that ENN B toxicity involves the inhibition of acyl-CoA: cholesterol acyl transferase (ACAT) activity and oxidative stress. ENN B also exerts cytotoxic activities by inducing mitochondrial modifications and cell cycle disruption, finally resulting in apoptotic cell death. Moreover, it produces adrenal endocrine toxicity. A recent study reports a potential anticancer activity. Nevertheless, regulatory limits have not yet been defined, due to a lack of complete toxicity data.⁸

Fumonisins B2

Fumonisin B2 is a mycotoxin produced by Fusarium growing on moldy corn (maize) grain. FB2 and Fumonisin B3 (FB3) occur in lower concentrations than FB1. FB1 and FB2 are approximately equal in structure and toxicity but naturally occur in a ratio of about 3:1 for FB1/FB2, thus has less toxicity than FB1.⁹

brantWellness 1360 Bayport Ave, Ste B. San Carlos, CA 94070

1(866) 364-0963 | support@vibrant-wellness.com | www. vibrant-wellness.com

L AST NAME PATIENT	FIRST NAMEGENDTESTMALE		-03-15	ACCESSI 2008260		ATE OF SERVICE
Frichothecene	2S					
Test Name (ng/g)	Species Name	In Control	Moderate	High	Current Levei	Previous Level (08/26/202 0)
Roridin E	Fusarium, Myrothecium, Stachybotrys	≤1.00	1.01~2.00	≥2.01	5.72	6.11
Verrucarin A	Fusarium, Myrothecium, Stachybotrys	≤1.00	1.01~2.00	≥2.01	7.97	5.03
Deoxynivalenol (Vomitoxin/DON)	Fusarium	≤50.60	50.61~101.20	≥101.21	4.26	4.50
Nivalenol (NIV)	Fusarium	≤2.40	2.41~4.80	≥4.81	5.81	3.80
diacetoxyscirpenol (DAS)	Fusarium	≤3.20	3.21~6.40	≥6.41	7.85	4.80
T-2 toxin	Fusarium	≤0.10	0.11~0.30	≥0.31	4.18	3.83
Satratoxin G	Stachybotrys chartarum	≤0.10	0.11~0.30	≥0.31	5.96	5.90
Satratoxin H	Stachybotrys chartarum	≤0.10	0.11~0.30	≥0.31	5.80	4.14
Isosatratoxin F	Stachybotrys chartarum	≤0.10	0.11~0.30	≥0.31	3.73	7.72
Roridin A	Stachybotrys chartarum	≤5.70	5.71~11.40	≥11.41	3.57	3.47
Roridin H	Stachybotrys chartarum	≤6.30	6.31~12.60	≥12.61	7.11	5.62
Roridin L-2	Stachybotrys chartarum	≤5.10	5.11~10.20	≥10.21	5.58	7.53
Verrucarin J	Sta <mark>chybo</mark> trys chartarum	≤6.90	6.91~13.80	≥13.81	6.70	6.70

Comments

Roridin E

Roridin E is a well-known macrocyclic trichothecene mycotoxin produced by various species of Fusarium, Myrothecium, Trichoderma, Trichothecium, Cephalosporium, Verticimonosporium, and Stachybotrys. They are produced on many different grains like wheat, oats or maize by various Fusarium species. Some molds that produce trichothecene mycotoxins, such as Stachybotrys chartarum, can grow in damp indoor environments and may contribute to health problems among building occupants.^o

Verrucarin A

Verrucarin A is macrocyclic trichothecenes are produced largely by Myrothecium, Stachybotrys and Fusarium. This toxin has a wide range of antiviral, antifungal and antibacterial activity. Trichothecenes are generally produced on many different grains like wheat, oats or maize. In early days, these macrocyclic trichothecene compounds structures were modified to create new anticancer agents.7

VibrantWellness 1360 Bayport Ave, Ste B. San Carlos, CA 94070

1(866) 364-0963 | support@vibrant-wellness.com | www. vibrant-wellness.com

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST	MALE	1998-03-15	2008260002	08-25-2020 14:55

Nivalenol (NIV)

Produced by the mold genus Fusarium, the type B trichothecenes, nivalenol (NIV) and their acetylated precursors are often contaminating cereal staples, posing a potential threat to public health that is still incompletely understood. Trichothecenes are very resistant to milling and processing, they can enter human food products easily. NIV is not found in food as commonly as DON; however, it demonstrates higher toxicity in animal studies. The toxicity of NIV is often compared to the toxicity of DON; however, the amount of toxicological data on NIV impact is much lower compared to DON.¹⁹

diacetoxyscirpenol (DAS)

Diacetoxyscirpenol (DAS), also known as anguidine, is a type A trichothecene mycotoxin primarily produced by Fusarium fungi. Trichothecenes are known as major contaminants of cereals and cereal-containing foods. DAS has been detected in agricultural products worldwide and persists in products after processing. In human as well as in animals, DAS consumption has been shown to induce haematological disorders (neutropenia, aplastic anemia). In the published literature, DAS has mainly been reported in various cereal grains (principally wheat, sorghum, maize, barley and oats) and cereal products, but also in potato products, soybeans and coffee. The highest levels have been reported for wheat, sorghum and coffee. DAS has been found to co-occur with many other mycotoxins in grains and grain-based products, in particular Fusarium toxins including type A and B trichothecenes, and zearalenone.²⁰

T-2 toxin

T-2 Toxin is a tricothecene produced by species of Fusarium and is one of the rare and deadlier toxins. If ingested in sufficient quantity, T-2 toxin can severely damage the entire digestive tract and cause rapid death due to internal hemorrhage. T-2 has been implicated in the human diseases alimentary toxic aleukia and pulmonary hemosiderosis. Damage caused by T-2 toxin is often permanent.

Satratoxin G

Satratoxin G is a macrocyclic trichothecene mycotoxin produced by commonly called black mold or Stachybotrys chartarum, that contribute to disorders associated with water-damaged buildings. They are potent inhibitors of protein translation that initiate both inflammatory gene expression and apoptosis in vitro after upstream activation of mitogen-activated protein kinases (MAPKs). These water-soluble mycotoxins could produce airborne particles which could facilitate entry and release into respiratory airway tissue that may selectively induce apoptosis in olfactory sensory neurons in the nose (rhinitis).²¹

Satratoxin H

Satratoxin H is a trichothecene mycotoxin that have been recognized as one of the potential etiologic agents in outbreaks of sick building syndromes. satratoxin H, potently inhibit protein synthesis and thymocyte proliferation and also can cause diseases such as an immune dysfunction and idiopathic pulmonary hemorrhage in infants. Recent studies have shown a possible relationship between trichothecenes and disorders of central nervous system including severe neuronal death.²²

Isosatratoxin F

Isosatratoxin F is another trichothecene produced by Stachybotrys chartarum. Several animal studies have shown that isosatratoxin F can cause nasal and pulmonary toxicity when administered intranasally or intratracheally. They showed that pulmonary alveolus cells were injured following intratracheal instillation of isosatratoxin F with marked changes in surfactant synthesis and secretion.²³

Roridin H

Roridin H is produced mainly by Stachybotrys and categorized as a trichothecene mycotoxin. There are reports showing the involvement of these trichothecene in the development of 'sick building syndrome'. These trichothecenes were found in air samples in the ventilation systems of private houses and office buildings, and on the walls of houses with high humidity. The symptoms of airborne toxicosis disappeared when the buildings and ventilation systems were thoroughly cleaned.²⁵

Roridin L-2

Roridin L2 is the putative biosynthetic precursor of Satratoxin G. It is a common trichothecene produced by S. chartarum isolates from water-damaged homes. Due to sturctural differences, roridin L2 possesses little in vitro or in vivo toxic activity as compared to SG.²⁶

	LAST NAME PATIENT	FIRST NAME TEST	GENDER MALE		0 F BIRTH	ACCESS		DATE OF SERVICE 08-25-2020 14:55	
$\left(\right)$	Urinary Creat	inine							-
	Test Name (mg/ml)	Species Nar	^{ne} C	ln Control	Moderate	High	Current Level		
	Urine Creatinine		0.2	25~2.16		≤0.24 ≥2.17	5.20	5.85	Ĵ

Mycotoxins

Key Terms/Glossary	
Mycotoxin	
in yestoxin	A toxic substance produced by a fungus
Antibacterial Compound	A compound active against bacteria to kill or remove them from the body
Antihelmintic Compound	A group of antiparasitic drugs that expel parasitic worms (helminths) and other internal
	parasites from the body by either stunning or killing them and without causing significant damage to the host.
Antifungal	A pharmaceutical fungicide or fungistatic used to treat and prevent mycosis.
Detoxification	Physiological or medicinal process of removal of toxic substances from a living organism, including the human body
Sick building syndrome	Medical condition where people in a building suffer from symptoms of illness or feel unwell for no apparent reason
Hepatocarcinoma	The most common primary liver tumor
Antischistosomal	An agent capable of affecting the viability of schistosomes
Sequestering agent	Nonabsorbable material capable of binding toxins in the gastrointestinal tract and reducing enterohepatic recirculation and ultimately the body burden of toxins.

Citations/Sources

- [1] Gurban, A. M.; Epure, P.; Oancea, F.; Doni, M., Achievements and Prospects in Electrochemical-Based Biosensing Platforms for Aflatoxin M₁ Detection in Milk and Dairy Products. Sensors (Basel, Switzerland) 2017, 17 (12).
- [2] Marchese, S.; Polo, A.; Ariano, A.; Velotto, S.; Costantini, S.; Severino, L., Aflatoxin B1 and M1: Biological Properties and Their Involvement in Cancer Development. Toxins 2018, 10 (6).
- [3] Bennett, J. W.; Klich, M., Mycotoxins. Clinical microbiology reviews 2003, 16 (3), 497-516.
- [4] Viegas, C.; Nurme, J.; Pieckova, E.; S, V., Sterigmatocystin in foodstuffs and feed: aspects to consider. Mycology 2018, 2018.
- [5] Mycotoxins and human health. IARC Sci Publ 2012, (158), 87-104.
- [6] Johanning, E.; Biagini, R.; Hull, D.; Morey, P.; Jarvis, B.; Landsbergis, P., Health and immunology study following exposure to toxigenic fungi (Stachybotrys chartarum) in a water-damaged office environment. International archives of occupational and environmental health 1996, 68 (4), 207-18.
- [7] Hughes, B. J.; Taylor, M. J.; Sharma, R. P., Effects of verrucarin A and roridin A, macrocyclic trichothecene mycotoxins, on the murine immune system. Immunopharmacology 1988, 16 (2), 79-87.
- [8] Prosperini, A.; Berrada, H.; Ruiz, M. J.; Caloni, F.; Coccini, T.; Spicer, L. J.; Perego, M. C.; Lafranconi, A., A Review of the Mycotoxin Enniatin B. Frontiers in Public Health 2017, 5, 304.
- [9] Peraica, M.; Radic, B.; Lucic, A.; Pavlovic, M., Toxic effects of mycotoxins in humans. Bull World Health Organ 1999, 77 (9), 754-66.
- [10] Turner, P. C.; Nikiema, P.; Wild, C. P., Fumonisin contamination of food: progress in development of biomarkers to better assess human health risks. Mutat Res 1999, 443 (1-2), 81-93.
- [11] Čulig, B.; Bevardi, M.; Bošnir, J.; Serdar, S.; Lasić, D.; Racz, A.; Galić, A.; Kuharić, Ž., PRESENCE OF CITRININ IN GRAINS AND ITS POSSIBLE HEALTH EFFECTS. African journal of traditional, complementary, and alternative medicines : AJTCAM 2017, 14 (3), 22-30.
- [12] Puel, O.; Galtier, P.; Oswald, I. P., Biosynthesis and toxicological effects of patulin. Toxins 2010, 2 (4), 613-31.
- [13] Pal, S.; Singh, N.; Ansari, K. M., Toxicological effects of patulin mycotoxin on the mammalian system: an overview. Toxicology research 2017, 6 (6), 764-771.
- [14] Hussein, H. S.; Brasel, J. M., Toxicity, metabolism, and impact of mycotoxins on humans and animals. Toxicology 2001, 167 (2), 101-34.
- **[15]** Mueller, A.; Schlink, U.; Wichmann, G.; Bauer, M.; Graebsch, C.; Schuurmann, G.; Herbarth, O., Individual and combined effects of mycotoxins from typical indoor moulds. Toxicology in vitro : an international journal published in association with BIBRA 2013, 27 (6), 1970-8.
- [16] Egbuta, M. A.; Mwanza, M.; Babalola, O. O., Health Risks Associated with Exposure to Filamentous Fungi. Int J Environ Res Public Health 2017, 14 (7).
- [17] Aleksic, B.; Draghi, M.; Ritoux, S.; Bailly, S.; Lacroix, M.; Oswald, I. P.; Bailly, J. D.; Robine, E., Aerosolization of mycotoxins after growth of toxinogenic fungi on wallpaper. Appl Environ Microbiol 2017.
- [18] Follmann, W.; Behm, C.; Degen, G. H., Toxicity of the mycotoxin citrinin and its metabolite dihydrocitrinone and of mixtures of citrinin and ochratoxin A in vitro. Arch Toxicol 2014, 88 (5), 1097-107.
- [19] Fogle, M. R.; Douglas, D. R.; Jumper, C. A.; Straus, D. C., Growth and mycotoxin production by Chaetomium globosum is favored in a neutral pH. Int J Mol Sci 2008, 9 (12), 2357-65.
- [20] Pestka, J., Toxicological mechanisms and potential health effects of deoxynivalenol and nivalenol. World Mycotoxin Journal 2010, 3 (4), 323-347.
- [21] Knutsen, H. K.; Alexander, J.; Barregård, L.; Bignami, M.; Brüschweiler, B.; Ceccatelli, S.; Cottrill, B.; Dinovi, M.; Grasl-Kraupp, B.; Hogstrand, C.; Hoogenboom, L.; Nebbia, C. S.; Oswald, I. P.; Petersen, A.; Rose, M.; Roudot, A.-C.; Schwerdtle, T.; Vleminckx, C.; Vollmer, G.; Wallace, H.; De Saeger, S.; Eriksen, G. S.; Farmer, P.; Fremy, J.-M.; Gong, Y. Y.; Meyer, K.; Parent-Massin, D.; van Egmond, H.; Altieri, A.; Colombo, P.; Horváth, Z.; Levorato, S.; Edler, L., Risk to human and animal health related to the presence of 4,15-diacetoxyscirpenol in food and feed. EFSA Journal 2018, 16 (8), e05367.
- [22] Hope, J., A Review of the Mechanism of Injury and Treatment Approaches for Illness Resulting from Exposure to Water-Damaged Buildings, Mold, and Mycotoxins. The Scientific World Journal 2013, 2013, 20.
- [23] Etzel, R. A., Mycotoxins. JAMA 2002, 287 (4), 425-7.

Citations/Sources

- [24] Wang, J. S.; Shen, X.; He, X.; Zhu, Y. R.; Zhang, B. C.; Wang, J. B.; Qian, G. S.; Kuang, S. Y.; Zarba, A.; Egner, P. A.; Jacobson, L. P.; Munoz, A.; Helzlsouer, K. J.; Groopman, J. D.; Kensler, T. W., Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. Journal of the National Cancer Institute 1999, 91 (4), 347-54.
- [25] Moosavi, M., Bentonite Clay as a Natural Remedy: A Brief Review. Iranian journal of public health 2017, 46 (9), 1176-1183.
- [26] Dvorak, M., [Ability of bentonite and natural zeolite to adsorb aflatoxin from liquid media]. Veterinarni medicina 1989, 34 (5), 307-16.
- [27] Renzulli, C.; Galvano, F.; Pierdomenico, L.; Speroni, E.; Guerra, M. C., Effects of rosmarinic acid against aflatoxin B1 and ochratoxin-A-induced cell damage in a human hepatoma cell line (Hep G2). Journal of applied toxicology : JAT 2004, 24 (4), 289-96.
- [28] Guilford, F. T.; Hope, J., Deficient glutathione in the pathophysiology of mycotoxin-related illness. Toxins 2014, 6 (2), 608-23.
- [29] Peterson, S.; Lampe, J. W.; Bammler, T. K.; Gross-Steinmeyer, K.; Eaton, D. L., Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food Chem Toxicol 2006, 44 (9), 1474-84.

Risk and Limitations

This test has been developed and its performance characteristics determined by Vibrant America LLC., a CLIA and CAP certified lab. These assays have not been cleared or approved by the U.S. Food and Drug Administration.

Mycotoxins do not demonstrate absolute positive and negative predictive values for mold related illnesses. Clinical history must be incorporated into the diagnostic determination. Quantification of mycotoxins in urine is not FDA-recognized diagnostic indicator of mold exposure.

Mycotoxins testing is performed at Vibrant America, a CLIA certified laboratory and utilizes ISO-13485 developed technology. Vibrant America has effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Examples include failure to obtain the result for a specific mycotoxin due to circumstances beyond Vibrant's control. Vibrant may re-test a sample in order to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested individual may wish to pursue further testing to verify any results.

The information in this report is intended for educational purposes only. While every attempt has been made to provide current and accurate information, neither the author nor the publisher can be held accountable for any errors or omissions.

Vibrant Wellness makes no claims as to the diagnostic or therapeutic use of its tests or other informational materials. Vibrant Wellness reports and other information do not constitute medical advice and are not a substitute for professional medical advice. Please consult your healthcare practitioner for questions regarding test results, or before beginning any course of medication, supplementation or dietary changes.